Pinnaql Acquires VEG, Broadening Manufacturing Compliance & Quality Services Platform

3 Boomerang Portfolio Company Closes Add-on Acquisition, Expanding the Platform’s Capabilities

, /PRNewswire/ — Pinnaql, Inc., a LSOMS Holdings, LP company, (“Pinnaql” or the “Company”), a 3 Boomerang Capital, LP (“3BC”) portfolio company, today announced it has acquired Validation & Engineering Group, Inc. (“VEG”), a leading provider of commissioning, qualification, and validation (“CQV”) services to the pharmaceutical and life sciences industries. The closing marks the second tuck-in acquisition the Company has made in the past eight months.

“VEG brings a proven 25+ year track record of technical excellence, client trust, and specialized manufacturing knowledge that is directly aligned with our mission,” said John Duffin, Chief Executive Officer of Pinnaql. “The team’s presence in key pharmaceutical manufacturing regions extends our geographic reach and will enable us to better serve clients with an even broader, integrated suite of services.”

Founded in 1997, VEG built its reputation through its deep engineering expertise across a range of CQV services. The Company’s foothold in pharmaceutical manufacturing and CQV services, coupled with its highly specialized engineering talent, offer immediate synergies with Pinnaql’s current specialization in laboratory validation and quality assurance.

VEG is the second strategic acquisition by LSOMS, following its acquisition of Pinnaql in June 2025. The deal further solidifies its position as a premier compliance, quality, and regulatory consulting platform for pharmaceutical and life sciences companies navigating increasingly complex compliance environments.

“We are thrilled to welcome VEG to the LSOMS platform,” said Peter Wen, Principal at 3 Boomerang Capital. “This acquisition exemplifies our commitment to building a best-in-class partner for life sciences companies seeking end-to-end quality, validation, and compliance expertise.”

About Pinnaql

Pinnaql (a LSOMS Holdings company) provides quality, regulatory, and operational excellence consulting to biopharmaceutical, medical device, and CDMO companies worldwide. The company’s mission is to deliver expert-driven, compliant solutions that empower clients to accelerate innovation and improve human health. Pinnaql supports life sciences organizations by ensuring operational readiness, reducing the risk of regulatory setbacks, and enabling clients to stay focused on advancing science, supporting patients, and bringing new therapies to market. As a trusted partner, Pinnaql elevates compliance and empowers innovation across the product lifecycle.

For more information, visit https://www.pinnaql.co

About 3 Boomerang Capital

3 Boomerang Capital, L.P. is a lower-middle-market healthcare private equity firm committed to fostering creative investment partnerships with healthcare entrepreneurs across North America and Western Europe. 3BC’s areas of investment focus span four key healthcare sectors: Biopharma outsourcing, medical device and diagnostic manufacturing, information technology and tech-enabled services, and alternate site care. The firm specializes in backing founder-led businesses, providing the guidance and resources needed for successful growth and innovation in the healthcare market. By strategically concentrating on four core areas, 3 Boomerang Capital is well-equipped to deliver on its mission of empowering healthcare entrepreneurs and propelling healthcare businesses to new heights. The firm is currently investing out of its flagship fund, 3 Boomerang Capital I, LP, a $376 million investment vehicle.

For more information, visit https://www.3boomerang.com/

Media Contact
Laura Simpson
JConnelly for 3 Boomerang Capital
[email protected]

SOURCE 3 Boomerang Capital